The purpose of this paper is to promote the medical treatment of colorectal cancer in our country and to save the lives of patients with colorectal cancer by studying mammalian target of rapamycin (mTOR) and the biologic information analysis of colorectal cancer.
We analyzed mTOR expression and survival differences using data from Coad & read from the TCGA public database and explored the coexpression regulatory network of mTOR. mTOR-regulated mirnas were screened using the Linked Omics database. In addition, we explored the association of mTOR with drug sensitivity, immune cell correlations, microsatellite deletions, tumor mutational burden, and mutational analysis.
The expression and survival of mTOR were significant different in colorectal cancer, and were related to the sensitivity of Bleomycin, Cisplatin and Gemcitabine. mTOR is associated with dendritic cell activation, NK cell dormancy, dendritic cell dormancy, and eosinophil granulocyte. mTOR is associated with microsatellite deletions, and tumor mutational load.
Based on these findings, we consumer mTOR as a biomarker for the diagnosis and prognosis of colorectal cancer.